Summary
The purpose of this randomized controlled Phase II study is to assess the efficacy of PDR001
versus investigator's choice of chemotherapy in patients with advanced nasopharyngeal
carcinoma (NPC).
By blocking the interaction between PD-1 and its ligands PD-L1 and PD-L2, PDR001 leads to the
activation of a T-cell mediated antitumor immune response.